MVP and Daiichi Signs Exclusive Distribution and License Agreement for Penthrox in China- Thailand- Vietnam
Shots:
- Medical Developments International (MVP) to receive up to $32.5M (AUD $45.8M) as total deal value plus $15M upfront and additional sales-based milestones payments
- MVP will fund the regulatory process of Penthrox in China and both companies will jointly collaborate with Japan’s service provider- EPS International Holdings for its approval. MVP will hold the drug import license rights on approval of Penthrox
- Penthrox is a non-opioid analgesic inhaler with fast-onset self-administered pain reliever. The agreement focuses on treatments for acute pain management in Chinese- Vietnamese and Thai markets
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
